FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia

Sponsor

National Cancer Institute (NCI) (NIH)

Overall Status

Completed

CT.gov ID

NCT00053963

Collaborator

(none)

Enrollment

Location

Arm

Study Details

Study Description

Brief Summary

This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

Condition or Disease	Intervention/Treatment	Phase
Blastic Phase Chronic Myelogenous Leukemia Childhood Central Nervous System Germ Cell Tumor Childhood Choroid Plexus Tumor Childhood Chronic Myelogenous Leukemia Childhood Craniopharyngioma Childhood Grade I Meningioma Childhood Grade II Meningioma Childhood Grade III Meningioma Childhood High-grade Cerebral Astrocytoma Childhood Infratentorial Ependymoma Childhood Low-grade Cerebral Astrocytoma Childhood Spinal Cord Neoplasm Childhood Supratentorial Ependymoma Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Recurrent Childhood Brain Stem Glioma Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Ependymoma Recurrent Childhood Medulloblastoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Recurrent Childhood Visual Pathway and Hypothalamic Glioma Refractory Chronic Lymphocytic Leukemia Relapsing Chronic Myelogenous Leukemia Unspecified Childhood Solid Tumor, Protocol Specific	Drug: romidepsin	Phase 1

Detailed Description

PRIMARY OBJECTIVES:

Determine the maximum tolerated dose (MTD) of FR901228 (depsipeptide) in pediatric patients with refractory or recurrent solid tumors.
Determine the dose-limiting toxic effects of this drug in these patients. III. Determine the pharmacokinetics of this drug in these patients. IV. Assess tolerability of this drug at the solid tumor MTD in patients with refractory or recurrent leukemia.
Determine, preliminarily, the antitumor activity of this drug in these patients.

OUTLINE: This is a dose-escalation, multicenter study.

Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients with solid tumors receive escalating doses of FR901228 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Cohorts of 3 patients (6 patients total) with leukemia receive FR901228 as above at the MTD.

Patients are followed for survival.

Study Design

Study Type:

Interventional

Actual Enrollment :

30 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A PHASE I STUDY OF DEPSIPEPTIDE (NSC#630176, IND# 51810) IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS AND LEUKEMIAS

Study Start Date :

Sep 1, 2002

Actual Primary Completion Date :

Feb 1, 2006

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm I Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	Drug: romidepsin Given IV Other Names: FK228 FR901228 Istodax

Arm

Intervention/Treatment

Experimental: Arm I

Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Drug: romidepsin

Given IV

Other Names:

FK228

FR901228

Istodax

Outcome Measures

Primary Outcome Measures

MTD, defined as that dose at which fewer than one-third of patients experience DLT, graded according to the NCI CTC version 2.0 [Up to 28 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A to 21 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically confirmed malignancy
Extracranial solid tumors or brain tumors*
Diagnosis of leukemia allowed after maximum tolerated dose is determined, including any of the following:
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic myelogenous leukemia in blast crisis
Disease must be refractory to conventional therapy or no effective conventional therapy exists
CNS tumors resulting in neurological deficits must be stable for 2 weeks before study entry
Performance status - Karnofsky 60-100% (over 10 years old)
Performance status - Lansky 60-100% (10 years old and under)
At least 8 weeks
Absolute neutrophil count at least 1,000/mm^3 (for solid tumor patients without bone marrow involvement)
Platelet count at least 100,000/mm^{3 (for solid tumor patients without bone marrow
involvement; platelet transfusion independent) OR 20,000/mm}3 (for leukemia patients; platelet transfusion allowed)
Hemoglobin at least 8.0 g/dL (RBC transfusions allowed)
Bilirubin no greater than 1.5 times upper limit of normal (ULN)
ALT no greater than 5 times ULN
Albumin at least 2 g/dL
Glomerular filtration rate at least 70 mL/min
Creatinine based on age as follows:
No greater than 0.8 mg/dL (for patients 5 years of age and under)
No greater than 1.0 mg/dL (for patients 6 to 10 years of age)
No greater than 1.2 mg/dL (for patients 11 to 15 years of age)
No greater than 1.5 mg/dL (for patients over 15 years of age)
Calcium normal (with or without supplementation)
Shortening fraction at least 27% by echocardiogram OR ejection fraction at least 50% by MUGA
No symptomatic congestive heart failure
No uncontrolled cardiac arrhythmia
QTc less than 450 msec
No evidence of dyspnea at rest
No exercise intolerance
Pulse oximetry greater than 94%
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 1 month after completion of study treatment
Magnesium and potassium normal (with or without supplementation)
No uncontrolled seizure disorder
No uncontrolled infection
No graft-vs-host disease
No seizure disorder unless well controlled and not on enzyme-inducing anticonvulsants
At least 1 week since prior growth factors
At least 3 weeks since prior biologic therapy or immunotherapy and recovered
At least 6 months since prior allogeneic stem cell transplantation
No concurrent routine prophylactic growth factors
At least 3 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered
No prior FR901228 (depsipeptide)
No other concurrent anticancer chemotherapy
Concurrent dexamethasone for CNS tumors allowed if on stable dose or decreasing dose for at least 1 week before study entry
Recovered from prior radiotherapy
At least 2 weeks since prior local palliative radiotherapy (small port)
At least 6 months since prior craniospinal radiotherapy or radiotherapy to at least 50% of pelvis
At least 6 weeks since other prior substantial bone marrow radiation
More than a 5 half-life washout period since prior and no concurrent medications associated with prolongation of QTc interval
No concurrent enzyme-inducing anticonvulsants
No concurrent hydrochlorothiazide
No other concurrent investigational drugs